0000000000469141
AUTHOR
K. Berneis
Should we routinely measure low-density and high-density lipoprotein subclasses?
Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) plasma populations are composed of heterogeneous subfractions that are different in size, density and protein/lipid content. There is increasing evidence that small, dense LDL particles are strongly associated with higher cardiovascular disease risk. Similarly, several studies have investigated whether smaller HDL particles are more protective than their larger counterparts and more recent findings suggest that small, dense HDL has significantly higher atheroprotective activity than larger L HDL. Yet, certain impairments of the protein/lipid content in small, dense HDL may decrease its antiatherogenic capacity or even induce p…
European Panel on Low Density Lipoprotein (LDL) Subclasses: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Item does not contain fulltext Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
Associations of fructose and glucose consumption with LDL particle size in the diet of healthy swiss men
Small, dense low-density lipoproteins are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome.
Who needs to care about small, dense low density lipoproteins?
Background: Increasing evidence suggest that the ‘quality’ rather than only the ‘quantity’ of low-density lipoprotein (LDL) exerts a great influence on the cardiovascular risk. Small, dense LDL seem to be an important predictor of cardiovascular events and progression of coronary artery disease (CAD) and their predominance has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. Discussion: Some studies showed in past years that small, dense LDL are usually elevated in patients at very high cardiovascular risk, such as those with CAD and type 2 diabetes. More recently elevated levels of these particles have been fou…
THE ATHEROGENIC LIPOPROTEIN PHENOTYPE AS PREDICTOR OF CARDIOVASCULAR EVENTS IN PATIENTS WITH NON-CORONARY FORMS OF ATHEROSCLEROSIS
COMPARATIVE EFFECTS OF ROSIGLITAZONE AND PIOGLITAZONE ON FASTING AND POSTPRANDIAL LDL-SIZE AND SUBCLASSES IN PATIENTS WITH TYPE-2 DIABETES
The Clinical Relevance of LDL Size and Subclasses Modulation in Patients with Type-2 Diabetes
increasing evidence suggest that the "quality" rather than only the "quantity" of low density lipoproteins (LDL) exerts a great influence on the cardiovascular risk. Hypertriglyceridemia, low HDL-cholesterol and increased levels of small dense LDL characterise diabetic dyslipidemia. in subjects with type-2 diabetes LDL size seems also to represent a good marker of clinical apparent and non-apparent atherosclerosis. Recently, the Coordinating Committee of the National Cholesterol Education Program stated that high-risk patients may benefit of stronger therapeutical approaches, a category of subjects that include those with type-2 diabetes. Screening for the presence of small, dense LDL may p…
The Role of Small, Dense LDL in Cardiovascular Risk: The Contributions of the Universities of Palermo and Zurich
A case of bowel schistosomiasis that did not adhere to the endoscopic findings.
Ezetimibe with or without simvastatin increases small dense low-density lipoproteins in healthy men – a randomized trial
Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter.
To test for intrinsic differences in metabolic properties of low-density lipoprotein (LDL) as a function of particle size, we examined the kinetic behavior of 6 human LDL fractions ranging in size from 251 to 265 A injected intravenously into human apolipoprotein (apo) B transgenic mice. A multicompartmental model was formulated and fitted to the data by standard nonlinear regression using the Simulation, Analysis and Modeling (SAAM II) program. Smaller sized LDL particles (251 to 257 A) demonstrated a significantly slower fractional catabolic rate (FCR) (0.050 +/- 0.045 h(-1)) compared with particles of larger size (262 to 265 A) (0.134 +/- -0.015 h(-1), P.03), and there was a significant …
Recent insights on atherogenic dyslipidemia and cardiovascular risk.
LDL size: does it matter?
The atherogenic lipoprotein phenotype is characterised by a moderate increase in plasma triglycerides, a decrease in high density lipoprotein cholesterol and the prevalence of smaller denser low density lipoprotein particles. The prevalence of this partially inheritable phenotype is approximately 30% and is a feature of the metabolic syndrome associated with an increased risk for cardiovascular events. The predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor by the adult treatment panel (ATP) III.